Clinical trial
Analysis of HIV Subtype A6 Genome in Patients With Virological Failure After Switching to Doravirine (DOR)
NCT05322083 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Analysis of HIV Subtype A6 Genome in Patients With Virological Failure After Switching to Doravirine (DOR)
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- May 31, 2022
- Completion date
- January 31, 2024
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
virus-hiv